Research programme: ion-channel modulators - Asana BioSciences

Drug Profile

Research programme: ion-channel modulators - Asana BioSciences

Alternative Names: ASN008; ASN009

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asana BioSciences
  • Class
  • Mechanism of Action Purinergic P2X3 receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Genitourinary disorders; Pain; Pruritus

Most Recent Events

  • 08 May 2018 Asana BioSciences intends to file an IND for ASN 008 for Pruritis and Pain, in the second half of 2018
  • 04 Jan 2018 Asana BioSciences plans a phase I trial of ASN-008 in unknown countries
  • 02 Dec 2015 Preclinical trials in Genitourinary disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top